Figure 2.
Elevated day +100 post-AHSCT absolute γδ T-cell count is significantly correlated with improved PFS and OS in all patients and in those who are MRD-negative. (A-B) For all patients at day +100 post-AHSCT, those with absolute γδ T-cell counts in the top 3 quartiles combined had improved PFS (P = .02) and OS (P = .01) compared with those in the lowest quartile. (C-D) For patients who had no detectable MRD (n = 60) by flow cytometry at day +100 post-AHSCT elevated absolute γδ T-cell count was significantly correlated with improved PFS (P = .02) and OS (P = .02). (E-F) For patients who had detectable MRD (n = 15) by flow cytometry at day +100 post-AHSCT, there was no significant correlation with elevated absolute γδ T-cell counts and PFS (P = .8) and OS (P = .5).

Elevated day +100 post-AHSCT absolute γδ T-cell count is significantly correlated with improved PFS and OS in all patients and in those who are MRD-negative. (A-B) For all patients at day +100 post-AHSCT, those with absolute γδ T-cell counts in the top 3 quartiles combined had improved PFS (P = .02) and OS (P = .01) compared with those in the lowest quartile. (C-D) For patients who had no detectable MRD (n = 60) by flow cytometry at day +100 post-AHSCT elevated absolute γδ T-cell count was significantly correlated with improved PFS (P = .02) and OS (P = .02). (E-F) For patients who had detectable MRD (n = 15) by flow cytometry at day +100 post-AHSCT, there was no significant correlation with elevated absolute γδ T-cell counts and PFS (P = .8) and OS (P = .5).

Close Modal

or Create an Account

Close Modal
Close Modal